Access to Intrathecal Baclofen Treatment for Children with Cerebral Palsy in European Countries: An SCPE Survey Reveals Important Differences
Access to Intrathecal Baclofen Treatment for Children with Cerebral Palsy in European Countries: An SCPE Survey Reveals Important Differences
复制标题
欧洲国家脑瘫儿童接受鞘内巴氯芬治疗的情况：一项 SCPE 调查揭示了重要差异
DOI：
10.1055/s-0040-1701659
复制
发表时间：
2020
期刊：
影响因子：
1.4
通讯作者：
J. De la Cruz
中科院分区：
文献类型：
--
作者：
K. Himmelmann;M. Påhlman;G. Andersen;T. Vik;D. Virella;K. Horridge;D. Neubauer;C. Arnaud;G. Rackauskaite;J. De la Cruz
摘要目的：研究欧洲脑瘫（CP）儿童鞘内注射巴氯芬（ITB）的情况，作为获得高级护理的指标。 方法：向CP注册机构、临床网络和泵制造商发送调查。 按性别、CP类型、粗大运动功能分类系统（GMFCS）水平和治疗开始时的年龄，对1990年至2005年出生的儿童进行了ITB治疗的调查。获得ITB与该国的国内生产总值（GDP）和用于卫生的GDP百分比有关。结果2011年，来自瑞典、挪威、英格兰、葡萄牙、斯洛文尼亚和丹麦的基于人群的数据显示，3，398例CP儿童中有114例（3.4%）接受了ITB治疗，各中心之间的比例为0.4%至4.7%。 大多数儿童的GMFCS水平为IV-V级，双侧痉挛性CP。在瑞典，运动障碍型CP是最常接受治疗的亚型。男孩接受ITB治疗的频率高于女孩（p = 0.014）。据报告，ITB可用于43个国家中的25个国家的CP儿童。获得ITB与较高的GDP和用于健康的GDP百分比相关（p < 0.01）。2019年的更新信息显示，ITB治疗的国家间差异和接受治疗儿童的性别差异仍然存在。结论：欧洲CP儿童的ITB访问存在显著差异。 接受治疗的男孩多于女孩。脑瘫儿童获得ITB的机会与国内生产总值和国内生产总值用于卫生的百分比有关。
Abstract Aim The aim is to study access to intrathecal baclofen (ITB) for children with cerebral palsy (CP) in Europe, as an indicator of access to advanced care. Methods Surveys were sent to CP registers, clinical networks, and pump manufacturers. Enquiries were made about ITB treatment in children born in 1990 to 2005 by sex, CP type, level of gross motor function classification system (GMFCS) and age at the start of treatment. Access to ITB was related to the country's gross domestic product (GDP) and % GDP spent on health. Results In 2011 population-based data from Sweden, Norway, England, Portugal, Slovenia, and Denmark showed that 114 (3.4%) of 3,398 children with CP were treated with ITB, varying from 0.4 to 4.7% between centers. The majority of the children were at GMFCS levels IV-V and had bilateral spastic CP. In Sweden, dyskinetic CP was the most commonly treated subtype. Boys were more often treated with ITB than girls (p = 0.014). ITB was reported to be available for children with CP in 25 of 43 countries. Access to ITB was associated with a higher GDP and %GDP spent on health (p < 0.01). Updated information from 2019 showed remaining differences between countries in ITB treatment and sex difference in treated children was maintained. Conclusion There is a significant difference in access to ITB for children with CP across Europe. More boys than girls are treated. Access to ITB for children with CP is associated with GDP and percent of GDP spent on health in the country.